A review and update on orphan drugs for the treatment of noninfectious uveitis

References

• Barisani-AsenbauerTMacaSMMejdoubiLEmmingerWMacholdKAuerHUveitis–a rare disease often associated with systemic diseases and infections – a systematic review of 2619 patientsOrphanet J Rare Dis201275722932001
   PubMed Web of Science ®Google Scholar
• JabsDANussenblattRBRosenbaumJTStandardization of Uveitis Nomenclature (SUN) Working GroupStandardization of uveitis nomenclature for reporting clinical data. Results of the First International WorkshopAm J Ophthalmol2005140350951616196117
   PubMed Web of Science ®Google Scholar
• GangaputraSNewcombCWLiesegangTLSystemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Methotrexate for ocular inflammatory diseasesOphthalmology2009116112188219819748676
   PubMed Web of Science ®Google Scholar
• LevyRAde AndradeFAFoeldvariICutting-edge issues in autoimmune uveitisClin Rev Allergy Immunol201141221422321913066
   PubMed Web of Science ®Google Scholar
• MetzingerJLFosterCS‘Approved for use in uveitis’: drug approval for an orphan diseaseExpert Opin Orphan Drugs201537799807
   Web of Science ®Google Scholar
• Developing Products for Rare Diseases & ConditionsDesignation an Orphan Product: Drug and Biological Products: Searchable Databases for Orphan Designated and or Approved Products. U.S. Food and Drug Administration2016 Available from: http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfmAccessed January 27, 2016
   Google Scholar
• GilmanAGRallTWNiesASTaylorPGoodman and Gilman’s the Pharmacological Basis of TherapeuticsNew York, NYPergamon Press1990
   Google Scholar
• WeinblattMECoblynJSFoxDAEfficacy of low dose methotrexate in rheumatoid arthritisN Engl J Med1985312138188223883172
   PubMed Web of Science ®Google Scholar
• ShahSSLowderCYSchmittMAWilkeWSKosmorskyGSMeislerDMLow-dose methotrexate therapy for ocular inflammatory diseaseOphthalmology1992999141914231407973
   PubMed Web of Science ®Google Scholar
• RossiSAustralian Medicines Handbook AdelaideAustraliaThe Australian Medicines Handbook Unit Trust2013
   Google Scholar
• Joint Formulary CommitteeBritish National Formulary (BNF)65th edLondon, UKPharmaceutical Press2013
   Google Scholar
• LimaBRNussenblattRBSenHNPharmacogenetics of drugs used in the treatment of ocular inflammatory diseasesExpert Opin Drug Metab Toxicol20139787588223521173
   PubMed Web of Science ®Google Scholar
• GalorAJabsDALederHAComparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammationOphthalmology2008115101826183218579209
   PubMed Web of Science ®Google Scholar
• ImrieFRDickADNonsteroidal drugs for the treatment of noninfectious posterior and intermediate uveitisCurr Opin Ophthalmol200718321221917435428
   PubMed Web of Science ®Google Scholar
• BaughmanRPLowerEEIngledueRKaufmanAHManagement of ocular sarcoidosisSarcoidosis Vasc Diffuse Lung Dis2012291263323311120
   PubMed Web of Science ®Google Scholar
• LarsonTNussenblattRBSenHNEmerging drugs for uveitisExpert Opin Emerg Drugs201116230932221210752
   PubMed Web of Science ®Google Scholar
• BachJHThe Mode of Action of Immunosuppressive DrugsAmsterdam, the NetherlandsElsevier1975
   Google Scholar
• TaylorSRHabot-WilnerZPachecoPLightmanSLIntraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edemaOphthalmology2009116479780119344827
   PubMed Web of Science ®Google Scholar
• KinoTHatanakaHHashimotoMFK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physicochemical and biological characteristicsJ Antibiot (Tokyo)1987409124912552445721
   PubMed Web of Science ®Google Scholar
• IshiokaMOhnoSNakamuraSFK506 treatment of noninfectious uveitisAm J Ophthalmol199411867237297526689
   PubMed Web of Science ®Google Scholar
• HoganACMcAvoyCEDickADLeeRWLong-term efficacy and tolerance of tacrolimus for the treatment of uveitisOphthalmology200711451000100617467532
   PubMed Web of Science ®Google Scholar
• LeeRWGreenwoodRTaylorHA randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitisOphthalmology201211961223123022381809
   PubMed Web of Science ®Google Scholar
• MurphyCCGreinerKPlskovaJCyclosporine vs tacrolimus therapy for posterior and intermediate uveitisArch Ophthalmol2005123563464115883282
   PubMedGoogle Scholar
• LeeYJKimSWSeoKYApplication for tacrolimus ointment in treating refractory inflammatory ocular surface diseasesAm J Ophthalmol2013155580481323394907
   PubMed Web of Science ®Google Scholar
• LindstedtEWBaarsmaGSKuijpersRWvan HagenPMAnti-TNF-alpha therapy for sight threatening uveitisBr J Ophthalmol200589553353615834077
   PubMed Web of Science ®Google Scholar
• SuhlerEBSmithJRGilesTRInfliximab therapy for refractory uveitis: 2-year results of a prospective trialArch Ophthalmol2009127681982219506209
   PubMed Web of Science ®Google Scholar
• AridaAFragiadakiKGiavriESfikakisPPAnti-TNF agents for Behcet’s disease: analysis of published data on 369 patientsSemin Arthritis Rheum2011411617021168186
   PubMed Web of Science ®Google Scholar
• SuhlerEBSmithJRWertheimMSA prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomesArch Ophthalmol2005123790391216009830
   PubMedGoogle Scholar
• SfikakisPPKaklamanisPHElezoglouAInfliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet diseaseAnn Intern Med2004140540440614996689
   PubMed Web of Science ®Google Scholar
• TabbaraKFAl-HemidanAIInfliximab effects compared to conventional therapy in the management of retinal vasculitis in Behcet diseaseAm J Ophthalmol20081466845.e1850.e118929351
   PubMed Web of Science ®Google Scholar
• RichardsJCTay-KearneyMLMurrayKMannersPInfliximab for juvenile idiopathic arthritis-associated uveitisClin Experiment Ophthalmol200533546146816181269
   PubMed Web of Science ®Google Scholar
• TynjalaPLindahlPHonkanenVLahdennePKotaniemiKInfliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritisAnn Rheum Dis200766454855017068061
   PubMed Web of Science ®Google Scholar
• ClementineRRLymanJZakemJMallepalliJLindseySQuinetRTumor necrosis factor-alpha antagonist-induced sarcoidosisJ Clin Rheumatol201016627427920808167
   PubMed Web of Science ®Google Scholar
• OlivierAGilsonBLafontaineSPautotJXBindiPPulmonary and renal involvement in a TNFα antagonist drug-induced sarcoidosisRev Med Interne2012335e25e2721592629
   PubMedGoogle Scholar
• Cordero-ComaMBenitoMFHernandezAMAntolinSCRuizJMSerpiginous choroiditisOphthalmology2008115916331633.e1e2.3618762076
   PubMed Web of Science ®Google Scholar
• DoychevaDDeuterCStuebigerNZierhutMInterferon-alpha-associated presumed ocular sarcoidosisGraefes Arch Clin Exp Ophthalmol2009247567568019034483
   PubMed Web of Science ®Google Scholar
• AlazemiSCamposMAInterferon-induced sarcoidosisInt J Clin Pract200660220121116451294
   PubMed Web of Science ®Google Scholar
• PlskovaJGreinerKForresterJVInterferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitisAm J Ophthalmol20071441556117601428
   PubMed Web of Science ®Google Scholar
• PlskovaJGreinerKMuckersieEDuncanLForresterJVInterferon-alpha: a key factor in autoimmune disease?Invest Ophthalmol Vis Sci20064793946395016936109
   PubMed Web of Science ®Google Scholar
• Tugal-TutkunIGuney-TefekliEUrganciogluMResults of interferon-alfa therapy in patients with Behcet uveitisGraefes Arch Clin Exp Ophthalmol2006244121692169516673135
   PubMed Web of Science ®Google Scholar
• BodaghiBGendronGWechslerBEfficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patientsBr J Ophthalmol200791333533917050581
   PubMed Web of Science ®Google Scholar
• BulterNJSuhlerEBRosenbaumJTInterferon alpha 2b in the treatment of cystoid macular edemaOcul Immunol Inflamm2012202869022409560
   PubMed Web of Science ®Google Scholar
• BeckerMDHeiligenhausAHuddeTInterferon as a treatment for uveitis associated with multiple sclerosisBr J Ophthalmol200589101254125716170111
   PubMed Web of Science ®Google Scholar
• CirinoACMathuraJRJrJampolLMResolution of activity (choroiditis and choroidal neovascularization) of chronic recurrent punctate inner choroidopathy after treatment with interferon B-1ARetina20062691091109217151504
   PubMed Web of Science ®Google Scholar
• MiserocchiEModoratiGBerchicciLPontikakiIMeroniPGerloniVLong-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitisBr J Ophthalmol2016100678278626396026
   PubMed Web of Science ®Google Scholar
• MiserocchiEPontikakiIModoratiGBandelloFMeroniPLGerloniVRituximab for uveitisOphthalmology2011118122322421199719
   PubMed Web of Science ®Google Scholar
• HeiligenhausAMiserocchiEHeinzCGerloniVKotaniemiKTreatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab)Rheumatology (Oxford)20115081390139421378109
   PubMed Web of Science ®Google Scholar
• HickmanRADennistonAKYeeCSToescuVMurrayPIGordonCBilateral retinal vasculitis in a patient with systemic lupus erythematodes and its remission with rituximab therapyLupus201019332732919900982
   PubMed Web of Science ®Google Scholar
• DavatchiFShamsHRezaipoorMRituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study)Int J Rheum Dis201013324625220704622
   PubMed Web of Science ®Google Scholar
• Tomkins-NetzerOTaylorSRLightmanSCan rituximab induce long-term disease remission in patients with intra-ocular non-infectious inflammation?Ophthalmologica2013230310911523948944
   PubMed Web of Science ®Google Scholar
• NicholsonLSobrinLAnterior uveitis secondary to type II essential cryoglobulinemiaJ Ophthalmic Inflamm Infect2013315623883484
   PubMedGoogle Scholar
• TappeinerCHeinzCGanserGHeiligenhausAIs tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?J Rheumatol201239612941295
   PubMed Web of Science ®Google Scholar
• TsangACRothJGottliebCTocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patientOcul Immunol Inflamm201422215515724377416
   PubMed Web of Science ®Google Scholar
• MesquidaMLeszczynskaALlorencVAdánAInterleukin-6 blockade in ocular inflammatory diseasesClin Exp Immunol2014176330130924528300
   PubMed Web of Science ®Google Scholar
• AdánAMesquidaMLlorencVTocilizumab treatment for refractory uveitis-related cystoid macular edemaGraefes Arch Clin Exp Ophthalmol2013251112627263223893042
   PubMed Web of Science ®Google Scholar
• MesquidaMMolinsBLlorencVSainz de la MazaMAdánALong-term effects of tocilizumab therapy for refractory uveitis-related macular edemaOphthalmology2014121122380238625204610
   PubMed Web of Science ®Google Scholar
• PapoMBielefeldPValletHTocilizumab in severe and refractory non-infectious uveitisClin Exp Rheumatol2014324 Suppl 84875879
   Web of Science ®Google Scholar
• HiranoTOhguroNHohkiSA case of Behcet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumabMod Rheumatol201222229830221748365
   PubMed Web of Science ®Google Scholar
• OshitariTKajitaFTobeARefractory uveitis in patient with castleman disease successfully treated with tocilizumabCase Rep Ophthalmol Med2012201296818023198204
   PubMedGoogle Scholar
• LinPTargeting interleukin-6 for noninfectious uveitisClin Ophthalmol201591697170226392750
   PubMed Web of Science ®Google Scholar
• WendlingDDernisEPratiCFrischEDelboscBOnset of inflammatory eye disease under tocilizumab treatment for rheumatologic conditions: a paradoxical effect?J Rheumatol20113810228421965707
   PubMed Web of Science ®Google Scholar
• CantariniLVitaleAScaliniPAnakinra treatment in drug-resistant Behcet’s disease: a case seriesClin Rheumatol20153471293130124305945
   PubMed Web of Science ®Google Scholar
• TeohSCSharmaSHoganALeeRRamananAVDickADTailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndromeBr J Ophthalmol200791226326417244662
   PubMed Web of Science ®Google Scholar
• AlexanderTKlotzOFeistERütherKBurmesterGRPleyerUSuccessful treatment of acute visual loss in Muckle-Wells syndrome with interleukin 1 receptor antagonistAnn Rheum Dis20056481245124616014694
   PubMed Web of Science ®Google Scholar
• ArósteguiJIArnaCMerinoRNOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin 1 blockade in a Spanish cohortArthritis Rheum200756113805381317968944
   PubMed Web of Science ®Google Scholar
• VitaleARiganteDCasoFInhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet’s disease: a case seriesDermatology2014228321121424642905
   PubMed Web of Science ®Google Scholar
• UgurluSUcarDSeyahiEHatemiGYurdakulSCanakinumab in a patient with juvenile Behcet’s syndrome with refractory eye diseaseAnn Rheum Dis20127191589159122586166
   PubMed Web of Science ®Google Scholar
• SimoniniGXuZCaputoRClinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitisArthritis Rheum201365251351823124805
   PubMed Web of Science ®Google Scholar
• BuggageRRLevy-ClarkeGSenHNA double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet’s diseaseOcul Immunol Inflamm2007152637017558830
   PubMed Web of Science ®Google Scholar
• IsaacsJDHaleGWaldmannHMonoclonal antibody therapy of chronic intraocular inflammation using Campath-1HBr J Ophthalmol19957911105410558534657
   PubMed Web of Science ®Google Scholar
• DickADMeyerPJamesTCampath-1H therapy in refractory ocular inflammatory diseaseBr J Ophthalmol200084110710910611109
   PubMed Web of Science ®Google Scholar
• LockwoodCMHaleGWaldmannHJayneDRRemission induction in Behcet’s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH-1HRheumatology (Oxford)200342121539154412949252
   PubMed Web of Science ®Google Scholar